Maxona Pharmaceuticals, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-06-13.
Maxona Pharmaceuticals, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on June 13, 2025. The filing reports $5.78M sold. Its industry group is Pharmaceuticals. It names Shahin Fatholahi (Executive Officer, Director), Behshad Sheldon (Director), David Nakamura (Director) (SEC Form D/A, June 13, 2025).
Is this your company?
Sell to companies like Maxona Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Maxona Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Maxona Pharmaceuticals, Inc., from the filings we hold.
Arcadia Securities, LLC received sales compensation on this raise and on 6 other raises we hold, nearest in date first:
Pharmaceuticals raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when Maxona Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Maxona Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Maxona Pharmaceuticals, Inc. →Get the full cited report on Maxona Pharmaceuticals, Inc.
What the filing shows about Maxona Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Maxona Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Maxona Pharmaceuticals, Inc.'s address as 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Maxona Pharmaceuticals, Inc. →
Amended on 2026-08-14: the offering size changed from $5,000,000 to $12,000,000; the amount sold changed from $900,163 to $5,778,673; the number of investors changed from 15 to 56; proceeds used for payments to executive officers, directors or promoters changed from $550,000 to $1,000,000; sales commissions changed from $68,865 to $412,064. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Maxona Pharmaceuticals, Inc. See pricing
Maxona Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1857448) and has filed since 2025-06-13. 2 filings are on record, the latest on 2026-08-14.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Maxona Pharmaceuticals, Inc.'s Form D of 2025-06-13 names Shahin Fatholahi, Behshad Sheldon, David Nakamura and 1 more as its officers, directors or promoters.
Its new offerings report $900K sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Shahin Fatholahi is named as Executive Officer and Director on the Form D that Maxona Pharmaceuticals, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
Behshad Sheldon is named as Director on the Form D that Maxona Pharmaceuticals, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
David Nakamura is named as Director on the Form D that Maxona Pharmaceuticals, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
Richard Brand is named as Executive Officer on the Form D that Maxona Pharmaceuticals, Inc. filed with the SEC on 13 June 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-06-13 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Maxona Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Maxona Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Maxona Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Maxona Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Maxona Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Maxona Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/maxona-pharmaceuticals-inc-form-d-25000001